<DOC>
	<DOCNO>NCT00442572</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy safety intermittent treatment PEGASYS HBeAg negative patient chronic hepatitis B demonstrate virological biochemical response treatment interferon alfa . After 48 week therapy interferon alfa , 24 week treatment-free follow-up , eligible patient randomize PEGASYS observational group . Those PEGASYS group receive 4 therapeutic cycle long term intermittent treatment PEGASYS ( 135 microgram sc weekly 12 week , follow treatment-free period 12 week ) observational arm receive specific antiviral treatment . The anticipated time study treatment 1-2 year , target sample size 100 individual .</brief_summary>
	<brief_title>SOFIA-LTT Study : A Study Intermittent Long Term Treatment With PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With HBeAg Negative Chronic Hepatitis B ( CHB ) .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; liver disease consistent CHB ; evidence chronic HBeAgnegative CHB prior initial course interferon alfa ; patient respond previous 48 week treatment interferon alfa . coinfection HCV , HDV HIV ; decompensated liver disease , hepatocellular cancer , evidence medical condition associate chronic liver disease viral hepatitis ; systemic antiviral , antineoplastic immunomodulatory treatment &lt; =6 month prior first dose randomize treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>